<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826628</url>
  </required_header>
  <id_info>
    <org_study_id>DSLP-01</org_study_id>
    <nct_id>NCT03826628</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex</brief_title>
  <official_title>A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermatology Specialties Limited Partnership</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermatology Specialties Limited Partnership</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the safety and efficacy of two different strengths of Rapamycin
      cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA)
      associated with Tuberous Sclerosis Complex (TSC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Topical rapamycin has previously been used to treat FA associated with TSC, reducing
      erythema, papule size, while flattening lesions and improving skin texture. Topical rapamycin
      has been reported to be well tolerated.

      The efficacy and safety of a topical rapamycin cream at two strengths (0.5% and 1.0%) will be
      assessed during a 26 week double-blind treatment phase with assessments made at clinical
      visits at baseline, 2, 8, 14, 20 and 26 weeks, and at follow-up (4 weeks after the last dose
      of study drug).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants obtaining successful treatment</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment success</measure>
    <time_frame>From first dose to 26 weeks</time_frame>
    <description>The time elapsed from the first dose to the time of treatment success, according to the IGA scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IGA</measure>
    <time_frame>At baseline and after 26 weeks treatment</time_frame>
    <description>The change in grading on the IGA scale from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FASI</measure>
    <time_frame>At baseline and after 26 weeks treatment</time_frame>
    <description>The change in grading on the Facial Angiofibroma Severity Index (FASI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective (participant or parent/caregiver) improvement rating</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Percentage improvement in FA since beginning treatment, as assessed by the participant or parent/caregiver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective (clinician) improvement rating</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Percentage improvement in FA since beginning treatment, as assessed by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in FA</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Change in FA since beginning treatment on a 5-point scale, as assessed by the participant or parent/caregiver</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Facial Angiofibroma</condition>
  <condition>Tuberous Sclerosis</condition>
  <arm_group>
    <arm_group_label>0.5% Rapamycin cream, topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0% Rapamycin cream, topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream topical, applied once daily before bed on affected area for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks</description>
    <arm_group_label>0.5% Rapamycin cream, topical</arm_group_label>
    <arm_group_label>1.0% Rapamycin cream, topical</arm_group_label>
    <other_name>sirolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients aged ≥ 6 years and ≤ 65 years on the day informed consent is
             obtained

          2. Patients diagnosed with TSC based on the clinical diagnostic criteria of International
             Tuberous Sclerosis Complex Consensus Conference 2012 and presenting visible facial
             angiofibroma

          3. An FA severity score of 2 or 3 on the IGA scale

          4. Patients or their legal representatives capable of understanding the explanation of
             the clinical trial and who give written informed consent for participation

          5. Patients or their legal representatives able to maintain patient diaries following the
             instructions of the investigator or sub-investigator

        Exclusion Criteria:

          1. Patients who cannot carry out the treatment plan or follow-up assessment

          2. Patients with serious skin lesions such as erosions or ulcers

          3. Patients with known hypersensitivity to any component of the study product

          4. Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3
             months of enrolment

          5. Patients who received laser therapy or surgical therapy within 6 months prior to trial
             enrolment

          6. Patients who participated in any other clinical trial within 3 months prior to the day
             of enrolment

          7. Patients judged unsuitable for this clinical trial by the investigator or
             sub-investigator

          8. Pregnant or lactating females

          9. Sexually active females of childbearing potential not using adequate contraception and
             sexually active males not using adequate contraception

         10. Patients with immune dysfunction or receiving any form of immunosuppression

         11. Patients with severe FA, with a score of 4 on the IGA scale

         12. Patients with an FA severity score of less than 2 on the IGA scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioana Stanescu</last_name>
    <role>Study Director</role>
    <affiliation>Dermatology Specialties Limited Partnership</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Zhang</last_name>
    <phone>+ 64 9 488 0232</phone>
    <phone_ext>710</phone_ext>
    <email>jenniferz@aftpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Badger</last_name>
      <email>kbadger@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Harper Price</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Israel Andrews</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Reit</last_name>
      <email>jreit@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Doris Trauner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Weiderhold</last_name>
      <email>aweider1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tatiana Restrepo</last_name>
      <email>trestre1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stacie Stapleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher L Russell</last_name>
      <email>christopher.russell@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven DeRoos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Pierce, CCRP</last_name>
      <phone>507-266-1078</phone>
      <email>pierce.katrina@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Megha M Tollefson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lily C Wong-Kisiel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Thompson</last_name>
      <email>src2h@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Derek Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Health Queensland</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Neylan</last_name>
      <phone>07 3069 7267</phone>
      <email>melissa.neylan@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kate Riney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pécs</name>
      <address>
        <city>Pécs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina ú Pavel</last_name>
      <phone>0314052573</phone>
      <email>VPavel@Hungarotrial.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Marchidanu</last_name>
      <phone>0314052573</phone>
      <email>dmarchidanu@hungarotrial.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kinga Hadzsiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canterbury District Health Board</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malina Storer</last_name>
      <phone>+64 3 364 1157</phone>
      <email>malina.storer@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Caroline Mahon, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Narodný ústav detských chorȏb</name>
      <address>
        <city>Bratislava</city>
        <zip>83340</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Pavel</last_name>
      <phone>031 405 2573</phone>
      <email>VPavel@Hungarotrial.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Marchidanu</last_name>
      <phone>0314052573</phone>
      <email>dmarchidanu@hungarotrial.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaroslava Payerova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Barrieutos</last_name>
      <phone>948255400</phone>
      <phone_ext>2742</phone_ext>
      <email>ibarrientos@unav.es</email>
    </contact>
    <investigator>
      <last_name>Leyre Aguado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Redondo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mar Garcia</last_name>
      <phone>913531920</phone>
      <phone_ext>7574</phone_ext>
      <email>mgarciai@unav.es</email>
    </contact>
    <investigator>
      <last_name>Marta Ivars</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Angiofibroma</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data is not planned to be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

